The efficacy of shikonin on cartilage protection in a mouse model of rheumatoid arthritis.
The potential therapeutic action of shikonin in an experimental model of rheumatoid arthritis (RA) was investigated. As a RA animal model, DBA/1J mice were immunized two times with type II collagen. After the second collagen immunization, mice were orally administered shikonin (2 mg/kg) once a day for 35 days, and the incidence, clinical score, bone mineral density (BMD), bone mineral content (BMC) and joint histopathology were evaluated. BMD in the proximal regions of the tibia largely increased in the shikonin treatment group compared with the control group. We also examined the effect of shikonin on inflammatory cytokines and cartilage protection. Shikonin treatment significantly reduced the incidence and severity of collagen-induced arthritis (CIA), markedly abrogating joint swelling and cartilage destruction. Shikonin also significantly inhibited the production of matrix metalloproteinase (MMP)-1 and up-regulated tissue inhibitors of metalloproteinase (TIMP)-1 in mice with CIA. In conclusion, shikonin exerted therapeutic effects through regulation of MMP/TIMP; these results suggest that shikonin is an outstanding candidate as a cartilage protective medicine for RA.
Kim
Young Ock
YO
Department of Herbal Crop Research, National Institute of Horticultural & Herbal Science, Rural Development Administration, Eumseong 369-873, Korea.
Hong
Seung Jae
SJ
Yim
Sung-Vin
SV
Rheumatology (Oxford). 2003 Jan;42(1):83-8
12509618
Arthritis Rheum. 2002 Jul;46(7):1926-36
12124878
FASEB J. 1991 May;5(8):2145-54
1850705
Yakugaku Zasshi. 1994 Jul;114(7):533-8
7932098
Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S54-8
14969051
Rheumatology (Oxford). 2002 Nov;41(11):1232-9
12421995
Ann Rheum Dis. 1998 Mar;57(3):158-61
9640131
J Ethnopharmacol. 2005 Dec 1;102(3):412-7
16054790
Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):739-51
16863437
Immunopharmacol Immunotoxicol. 1996 Feb;18(1):105-14
8683032
J Bone Miner Res. 2003 Jul;18(7):1206-16
12854830
Jikken Dobutsu. 1990 Jan;39(1):27-34
2303092
Bone. 2001 Jan;28(1):87-93
11165947
Rheumatol Int. 2011 May;31(5):595-603
20049449
Bone. 2002 Feb;30(2):340-6
11856640
Clin Exp Immunol. 1993 Oct;94(1):145-9
8403497
J Rheumatol. 2004 Feb;31(2):238-42
14760791
Biol Pharm Bull. 2007 May;30(5):928-34
17473437
Korean J Physiol Pharmacol. 2009 Dec;13(6):417-24
20054486
Nat Protoc. 2007;2(5):1269-75
17546023
Curr Opin Rheumatol. 2000 May;12(3):195-9
10803748
Ann Rheum Dis. 2002 Nov;61(11):975-80
12379519
Angew Chem Int Ed Engl. 1999 Feb 1;38(3):270-301
29711637
Endocrinology. 1984 Jul;115(1):50-4
6547388
Trends Genet. 1990 Apr;6(4):121-5
2132731
J Rheumatol. 1995 Apr;22(4):600-6
7540690
Agents Actions. 1982 Dec;12(5-6):650-6
7164936